319 related articles for article (PubMed ID: 15758718)
1. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
Kundu SD; Grubb RL; Roehl KA; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1116-20. PubMed ID: 15758718
[TBL] [Abstract][Full Text] [Related]
2. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
4. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
Catalona WJ; Smith DS; Ratliff TL; Basler JW
JAMA; 1993 Aug; 270(8):948-54. PubMed ID: 7688438
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening in the Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
Mettlin C; Murphy GP; Lee F; Littrup PJ; Chesley A; Babaian R; Badalament R; Kane RA; Mostofi FK
Cancer; 1993 Sep; 72(5):1701-8. PubMed ID: 7688658
[TBL] [Abstract][Full Text] [Related]
8. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Schröder FH; van der Maas P; Beemsterboer P; Kruger AB; Hoedemaeker R; Rietbergen J; Kranse R
J Natl Cancer Inst; 1998 Dec; 90(23):1817-23. PubMed ID: 9839522
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
12. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection at low prostate specific antigen.
Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
[TBL] [Abstract][Full Text] [Related]
14. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
Vis AN; Hoedemaeker RF; Roobol M; van der Kwast TH; Schröder FH
Prostate; 2001 Jun; 47(4):252-61. PubMed ID: 11398172
[TBL] [Abstract][Full Text] [Related]
15. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
16. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
17. Results of compliance with prostate cancer screening guidelines.
Grubb RL; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2005 Aug; 174(2):668-72; discussion 672. PubMed ID: 16006944
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer].
Oeda T; Kusumi N; Takamoto A
Nihon Hinyokika Gakkai Zasshi; 2010 Jan; 101(1):18-24. PubMed ID: 20158074
[TBL] [Abstract][Full Text] [Related]
20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
